

## Exhibit A

**BEST AVAILABLE COPY**

**Bruce L. Roberts**  
Vice President, Applied Genomics  
Genzyme Molecular Oncology  
1 Mountain Road  
Framingham MA 01701  
Work (508)-270-2428  
E-mail: bruce.roberts@genzyme.com

#### **EMPLOYMENT**

1983-1985 Scientific Officer, Biochemistry Division, National Institute for Medical Research, London, England

1985-1987 Research Scientist, Protein Engineering Group, Integrated Genetics, Framingham, Massachusetts

1987-1988 Staff Scientist I, Transgenic Group, Integrated Genetics

1988-1989 Staff Scientist II, Head of Molecular Biology, Transgenic Group, Integrated Genetics (now Genzyme)

1989-1995 Senior Staff Scientist, Protein Engineering Corporation (now Dyax)

1995-1996 Senior Staff Scientist, Gene Therapy, Genzyme Corporation, Framingham, Massachusetts

1996-1997 Associate Director, Gene Therapy, Genzyme Corporation

1997-1999 Director, Cancer Gene Therapy, Genzyme Molecular Oncology

1999-2000 Senior Director, Cancer Gene Therapy, Genzyme Molecular Oncology

2000-present Vice President, Applied Genomics, Genzyme Molecular Oncology

#### **EDUCATION**

1974-1978 B.Sc. (Biochemistry), Carleton University, Ottawa, Canada

1978-1983 Ph.D. (Protein Chemistry) University of Ottawa, Ottawa, Canada

## **AWARDS AND SCHOLARSHIPS RECEIVED**

University of Ottawa Entrance Scholarship (1978-1980)

Canadian National Science and Engineering Research Council Postgraduate Scholarship  
(1979-1982)

## **OTHER DISTINCTIONS**

Invited Speaker-1986 Penn State Symposium on Molecular Biology: The Nucleus

Invited Speaker-1988 Virginia Polytech Symposium on Large Animal Transgenics

Invited Speaker- 1989 AgBiotech Conference, Arlington, Virginia

Invited Speaker- 1997 NMHCC on Immunotherapy of Cancer , Bethesda, MD

Invited Speaker- 1998 CHI conference on New Technologies and Applications of  
Vaccines, Palm Beach, Florida

Invited Speaker- 1998 IBC conference on Cancer Gene Therapy, London, UK

Invited Speaker- 1999 IIR conference on Clinical Evaluation of 2<sup>nd</sup> Generation Cancer  
Vaccines, London, UK

Invited Speaker-1999 IBC conference on Immunotherapy for cancer, San Diego

Invited Speaker- 2000 Sabin Institute Colloquium on Cancer Vaccines, Walker's Cay

Co-author of NIH RO1 Grant Application (No CA43186) entitled  
"Mutagenesis of Papovavirus Transforming Proteins (awarded for the period 1986-1991)

## PUBLICATIONS

Roberts, B. and Anderson, P.J. (1985). The purification and kinetic characterization of cel white muscle pyruvate kinase. *Comp. Biochem. Physiol.* (B) 80, 51-56.

Kalderon, D., Roberts, B.L., Richardson, W.D. and Smith, A.E. (1984). A short amino acid sequence able to specify nuclear location. *Cell* 39, 499-509.

Smith, A.E., Kalderon, D., Roberts, B.L., Colledge, W.D., Edge, M., Gillett, P., Markham, A.F., Paucha, E. and Richardson, W.D. (1985). The nuclear location signal. *Proc. Royal Soc. (London)* (B) 226, 43-58.

Smith, A.E., Markland, W., Cheng, S. and Roberts, B.L. (1985) Papovavirus transforming proteins. In: *The 12th Symposium for Comparative Research on Leukemia and Related Diseases*, pp. 76-93.

Markland, W., Cheng, S.H., Roberts, B.L., Harvey, R. and Smith, A.E. (1986). Transformation-associated domains of polyoma virus middle-T antigen. In: *Cancer Cells 4*, Cold Spring Harbor Laboratory, pp. 373-379.

Richardson, W.D., Roberts, B.L. and Smith, A.E. (1986). Nuclear location signals in polyoma virus large-T. *Cell* 44, 77-85.

Roberts, B.L., Richardson, W.D., Kalderon, D., Cheng, S.H., Markland, W. and Smith, A.E. (1986). Amino acid sequences able to confer nuclear location. In: *Nucleocytoplasmic Transport*, R. Peters and M. Trendelenburg, eds. (Berlin: Springer-Verlag), pp. 185-198.

Roberts, B.L., Richardson, W.D. and Smith, A.E. (1987). The effect of protein context on nuclear signal function. *Cell* 50, 465-475.

Markland, W., Smith, A.E. and Roberts, B.L. (1987). Signal-dependent translocation of simian virus 40 large-T antigen into rat liver nuclei in a cell-free system. *Molec. Cell. Biol.* 7, 4255-4265.

Rawle, F.C., O'Connell, K.A., Geib, R.W., Roberts, B. and Gooding, L.R. (1988). Fine mapping of an H-2KK restricted CTL epitope in SV40 T antigen using in-frame deletion mutants and a synthetic peptide. *J. Immunol.* 141, 2734-2739.

Dingwall, C., Robbins, J., Dilworth, S.M., Roberts, B. and Richardson, W.D. (1988). The nucleoplasmin nuclear location sequence is larger and more complex than that of SV40 large T antigen. *J. Cell Biol.* 107, 841-849.

Gordon, K., Vitale, J., Roberts, B., Monastersky, G., DiTullio, P. and Moore, G. (1989). Expression of foreign genes in the lactating mammary gland of transgenic animals. In: UCLA Symposia on Molecular and Cellular Biology-New Series 116, 55-60.

Roberts, B., Vitale, J., Capalucci, N., Monastersky, G., DiTullio, P. and Gordon, K. (1989). Expression of human genes in transgenic animals. In: Proceedings of the AgBiotech'89 Conference, pp. 300-303.

Roberts, B.L. (1989). Nuclear location signal-mediated protein transport. B.B.A. 1008, 263-280.

Roberts, B.L., DiTullio, P., Vitale, J., Hehir, K. and Gordon, K. (1992). Cloning of the goat B-casein-encoding gene and expression in transgenic mice. Gene 121, 255-262.

Markland, W., Roberts, B.L., Saxena, M.J., Guterman, S.K. and Ladner, R.C. (1991). Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13. Gene 109, 13-19.

Roberts, B.L., Markland, W., Ley, A.C., Kent, R.B., White, D.W., Guterman, S.K. and Ladner, R.C. (1992). Directed evolution of a protein: selection of potent new neutrophil elastase inhibitors displayed on M13 fusion phage. Proc. Natl. Acad. Sci. USA 89, 2429-2433.

Roberts, B.L., Markland, W., Siranosian, K., Saxena, M.J., Guterman, S.K. and Ladner, R.C. (1992). Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors. Gene 121, 9-15.

Ebert, K.M., DiTullio, P., Barry, C.A., Schindler, J.E., Ayres, S.L., Smith, T.E., Pellerin, L.J., Meade, H.M., Denman, J. and Roberts, B. (1994) Induction of human tissue plasminogen activator in the mammary gland of transgenic goats. Bio/Technology 12: p. 699-702.

Roberts, B.L., Markland, W. and Ladner, R.C. (1996) Affinity maturation of proteins displayed on surface of M13 bacteriophage as major coat protein fusions. Methods in Enzymology 267: p. 68-82.

Markland, W., Roberts, B.L. and Ladner, R.C. (1996) Selection for protease inhibitors using bacteriophage display. Methods in Enzymology 267: p. 28-51.

Murphy, S., Turner, G., Piper, T., Roberts, B., Wadsworth, S., Smith, A.E., Wells, D.J. and Dickson, G. (1996) Adenoviral vectors for gene transfer of full length human dystrophin cDNAs. Biochemical Society Transactions 24: p. 277S.

Havenga, M., Fisher, R., Hoogerbrugge, P., Roberts, B., Valerio, D. and van Es, H.H.G. (1997) Development of safe and efficient retroviral vectors for Gaucher disease. *Gene Therapy* 4: p. 1393-1400.

Zhai, Y., Yang, J.C., Spiess, P., Nishimura, M.I., Overwijk, W.W., Roberts, B., Restifo, N.P., and Rosenberg, S.A. (1997) Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. *Journal of Immunotherapy* 20: p. 15-25

Castleden, S.A., Chong, H., Garcia-Ribas, I., Melcher, A.A., Hutchinson, G., Roberts, B., Hart, I.R. and Vile, R.G. (1997) A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. *Human Gene Therapy* 8: p. 2087-2102.

Rosenberg, S.A., Zhai, Y., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Seipp, C.A., Einhorn, J.H., Roberts, B. and White, D.E. (1998) Immunization of patients with metastatic melanoma using recombinant adenoviruses encoding the MART-1 or gp100 melanoma antigens. *Journal of the National Cancer Institute* 90: p. 1894-1900.

Kaplan, J.M., Yu, Q., Piraino, S.T., Pennington, S.E., Shankara, S., Woodworth, L.A. and Roberts, B.L. (1999) Induction of anti-tumor immunity using dendritic cells transduced with adenovirus vector encoding endogenous tumor associated antigens. *Journal of Immunology* 163: p. 699-707.

Wan, Y., Emtage, P., Zhu, Q., Foley, R., Pilon, A., Roberts, B. and Gauldie, J. (1999) Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. *Cellular Immunology* 198: p. 131-138.

Mohr, L., Shankara, S., Yoon, S.-K., Krohne, T.U., Geissler, M., Roberts, B., Blum, H.E. and Wands, J.R. (2000) Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. *Hepatology* 31: p. 606-614

Linette, G.P., Shankara, S., Longerich, S., Yang, S., Doll, R., Nicolette, C., Preffer, F.I., Roberts, B.L. and Haluska, F.G. (2000) In vitro priming with adenovirus/gp100 antigen transduced dendritic cells reveals the epitope specificity of HLA-A201 restricted CD8+ T cells in patients with melanoma. *Journal of Immunology* 164: p. 3402-3412.

Perricone, M.A., Claussen, K.A., Smith, K.A., Kaplan, J.M., Piraino, S., Shankara, S. and Roberts, B.L. (2000) Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma associated antigens. *Molecular Therapy* 1: p. 275-284.

Roberts, Bruce "Adenovirus and Other Viral Vaccines" in *Principles and Practice of the Biological Therapy of Cancer*, 3<sup>rd</sup> edition. S. A. Rosenberg, ed. Chapter 18.6.

Gnjatic, S., Nagata, Y., Jager, E., Stockert, E., Shankara, S., Roberts, B.L., Mazzara, G.P., Lee, S.Y., Dunbar, P.R., Dupont, B., Cerundolo, V., Ritter, G., Chen, Y.-T., Knuth, A. and Old, L.J. (2000) Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. *P.N.A.S. (USA)* 97: p. 10917-10922.

**PATENTS**

R.C. Ladner, S.K. Guterman, B.L. Roberts, W. Markland, A.C. Ley and R.B. Kent  
Directed Evolution of Novel Binding Proteins  
US Patent 5,837,500

R.C. Ladner, S.K. Guterman, B.L. Roberts, W. Markland, A.C. Ley and R.B. Kent  
Directed Evolution of Novel Binding Proteins  
US Patent 5,571,698

A.C. Ley, R.C. Ladner, S.K. Guterman, B.L. Roberts, W. Markland, and R.B. Kent  
Engineered Human-Derived Kunitz Domains that Inhibit Human Neutrophil Elastase  
US Patent 5,663,143

R.C. Ladner, S.K. Guterman, B.L. Roberts, W. Markland, A.C. Ley and R.B. Kent  
Human Neutrophil Elastase and Human Cathepsin G Inhibitors (Filed 2/28/92)  
Priority Date of March 1, 1991 (Filing Date of US 07/664,989)

R.C. Ladner, B.L. Roberts, A.C. Ley and R.B. Kent  
Process for the Development of Binding Mini-Proteins (Filed 2/27/92)  
Priority Date of March 1, 1991 (Filing Date of US 07/664,989)

R.C. Ladner, S.K. Guterman, B.L. Roberts, W. Markland, A.C. Ley, and R.B. Kent  
Improved Epitope Displaying Phage (Filed 2/28/92)  
Priority Date of March 1, 1991 (Filing Date of US 07/664,989)

**Additional Filed Applications entitled:**

Methods for Identifying Therapeutic Targets

Methods of Generating Antigen-Specific Cells and Uses Thereof

Compositions and Methods for Gene-Based Vaccines to Provoke T cell  
Responses



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**